Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy.
| Autor: | Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2/1/2011, Vol. 29 Issue 4, p398-405, 8p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|